Clinical Trial Update: Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial comparing rasburicase to allopurinol in cancer patients at risk for hyperuricemia and tumor lysis syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hyperuricemia
• Tumor Lysis Syndrome

Drugs mentioned

• Allopurinol (Allopurinol)
• Rasburicase (rasburicase)

Snippet

Sponsor: Sanofi | Conditions: Tumor Lysis Syndrome, Cancer | Phase 3 | Status: COMPLETED | Results posted: 2009-12-31